{"id":75368,"date":"2021-01-04T19:11:15","date_gmt":"2021-01-04T13:41:15","guid":{"rendered":"https:\/\/blog.forumias.com\/?p=75368"},"modified":"2021-03-05T12:37:11","modified_gmt":"2021-03-05T07:07:11","slug":"approval-to-covaxin-and-covishield-vaccines-concerns-and-way-forward","status":"publish","type":"post","link":"https:\/\/forumias.com\/blog\/approval-to-covaxin-and-covishield-vaccines-concerns-and-way-forward\/","title":{"rendered":"Approval to Covaxin, and Covishield Vaccines: Concerns and way forward"},"content":{"rendered":"<p><span style=\"color: #ff0000;\"><em><span style=\"font-family: georgia, palatino, serif;\"><strong>This article has been developed based on the Indian Express article \u201cTurning point\u201d. <\/strong><\/span><\/em><\/span><\/p>\n<p><span style=\"font-family: georgia, palatino, serif;\"><strong>Synopsis-<\/strong>\u00a0The Drug Controller General of India (DCGI) approved two vaccines \u2014 the indigenously developed Covaxin, and Covishield. There are several concerns associated with the hasty approval of vaccines.<\/span><\/p>\n<p><span style=\"font-family: georgia, palatino, serif; font-size: 14pt;\"><strong>About Vaccines <\/strong><\/span><\/p>\n<p><span style=\"font-family: georgia, palatino, serif; font-size: 14pt;\"><strong>COVISHIELD:<\/strong><\/span><\/p>\n<ul>\n<li><span style=\"font-family: georgia, palatino, serif;\">This vaccine is incubated in the laboratories of Oxford University and Swedish-British pharma firm, AstraZeneca. It is manufactured by the Serum Institute of India.<\/span><\/li>\n<li><span style=\"font-family: georgia, palatino, serif;\"><strong>Type of vaccine:<\/strong>\u00a0It is made from a weakened version of a common cold adenovirus that causes infections in chimpanzees.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: georgia, palatino, serif; font-size: 14pt;\"><strong>COVAXIN:<\/strong><\/span><\/p>\n<ul>\n<li><span style=\"font-family: georgia, palatino, serif;\">It has been indigenously developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).<\/span><\/li>\n<li><span style=\"font-family: georgia, palatino, serif;\">Approval of this vaccine has raised many concerns as the Vaccine was still undergoing phase-3 clinical trials.<\/span><\/li>\n<\/ul>\n<p><strong><span style=\"font-family: georgia, palatino, serif; color: #ff0000;\"><a style=\"color: #ff0000;\" href=\"https:\/\/forumias.com\/blog\/factly-news-articles-for-upsc-prelims-jan-042021\/\">Read More about Vaccines<\/a><\/span><\/strong><\/p>\n<p><span style=\"font-family: georgia, palatino, serif;\">As per the regulators, Phase I and Phase II clinical trials were conducted on approximately 800 subjects and the results have demonstrated that the vaccine is safe and provides a robust immune response.\u00a0<\/span><\/p>\n<p><span style=\"font-family: georgia, palatino, serif;\">An efficacy trial of this vaccine was initiated in India on 25,800 volunteers, and the data provided till now has been found to be safe, according to regulators.<\/span><\/p>\n<p><span style=\"font-family: georgia, palatino, serif;\">However, there is no clarity about the type of data available.<\/span><\/p>\n<p><span style=\"font-family: georgia, palatino, serif; font-size: 14pt;\"><strong>Conditions associated with approval <\/strong><\/span><\/p>\n<ul>\n<li><span style=\"font-family: georgia, palatino, serif;\">The emergency use approval is conditional on the vaccine developers submitting details of any adverse effect to the drug regulator, every 15 days.\u00a0<\/span><\/li>\n<li><span style=\"font-family: georgia, palatino, serif;\">A factsheet with safety details will also be provided to those receiving the first lot of vaccines.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: georgia, palatino, serif; font-size: 14pt;\"><strong>Accelerated approval process in India <\/strong><\/span><\/p>\n<p><span style=\"font-family: georgia, palatino, serif;\">The term \u201cEmergency Use Authorisation (EUA)\u201d has been used mainly by regulatory agencies like FDA in the US and some other countries.<\/span><\/p>\n<p><span style=\"font-family: georgia, palatino, serif;\">The term Emergency Use Authorisation (EUA) has not been used anywhere in rules in India. However, 2019 rules provide for an \u201cAccelerated Approval Process\u201d for granting approval to a drug that is still in clinical trials. The definition of a new drug in the 2019 Rules includes a vaccine.<\/span><\/p>\n<p><span style=\"font-family: georgia, palatino, serif;\"><strong>Conditions for Accelerated Approval Process<\/strong><\/span><\/p>\n<ul>\n<li><span style=\"font-family: georgia, palatino, serif;\">There should be a prima facia case that the drug is of Therapeutic benefits.<\/span><\/li>\n<li><span style=\"font-family: georgia, palatino, serif;\">\u201cAccelerated approval may also be granted to a new drug if it is intended for the treatment of a serious, or life-threatening condition, or disease of special relevance to the country, and addresses unmet medical needs,\u201d.<\/span><\/li>\n<li><span style=\"font-family: georgia, palatino, serif;\">Approval can be granted even if \u201cremarkable\u201d effectiveness is reported even from phase-II trials.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: georgia, palatino, serif;\">Approval granted to drugs or vaccines that are still in clinical trials is temporary, and valid only for one year.<\/span><\/p>\n<p><span style=\"font-family: georgia, palatino, serif; color: #ff0000;\"><strong>Read more<\/strong> &#8211; <a style=\"color: #ff0000;\" href=\"https:\/\/forumias.com\/blog\/process-and-issues-linked-to-emergency-use-authorisation-eua-of-covid-vaccines-in-india\/\">Emergency Use authorisation of vaccines<\/a><\/span><\/p>\n<p><span style=\"font-family: georgia, palatino, serif; font-size: 14pt;\"><strong>What are the concerns associated with the hasty approval of vaccines? <\/strong><\/span><\/p>\n<p><span style=\"font-family: georgia, palatino, serif;\">India which is regarded as a manufacturer of vaccines, has put its credibility at a stake by this hasty approval of vaccine. It has raised a wave of concerns by scientific and healthcare communities about a \u201cpublic rollout of an untested product.\u00a0<\/span><\/p>\n<ul>\n<li><span style=\"font-family: georgia, palatino, serif;\"><strong>First,\u00a0Covaxin\u00a0has been approved without clinical efficacy data. <\/strong>This vaccine was on the 3<sup>rd<\/sup> stage, which is always a key to prove its efficiency. Government\u2019s approval to this vaccine might hurt India\u2019s credibility in case of any adverse impacts.\u00a0\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"font-family: georgia, palatino, serif;\">Efficacy data is an indication of how effective the vaccine is in preventing the virus attack.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li><span style=\"font-family: georgia, palatino, serif;\"><strong>Second, As regulators have themselves evaded their rules, credibility of regulator at stake-<\/strong>\u00a0This lack of transparency could lead to a lack of trust in the vaccine.\u00a0There are several issues with the way the approval has been granted, which can lead to people losing confidence in the regulatory system.\u00a0<\/span><\/li>\n<li><span style=\"font-family: georgia, palatino, serif;\"><strong>Third,\u00a0<\/strong>approval an untested vaccine makes it nearly\u00a0<strong>impossible to conduct a proper phase-3 trial.<\/strong>\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"font-family: georgia, palatino, serif;\">It will be unethical to expect volunteers to participate in a trial where there is only a 50% chance of being administered the actual vaccine, when they have the option of the real dose elsewhere.<\/span><\/li>\n<\/ul>\n<\/li>\n<li><span style=\"font-family: georgia, palatino, serif;\"><strong>Fourth,\u00a0While <\/strong>Pharmaceutical giants like Pfizer, Moderna, and AstraZeneca have given a go-ahead only after partial results of <strong>vaccine\u2019s abilities in their own populations<\/strong>, In India Covishield has not been tested for\u00a0<strong>vaccine ability among Indian population.<\/strong><\/span>\n<ul>\n<li><span style=\"font-family: georgia, palatino, serif;\">As it is a possibility that vaccine response among Indian population may not be the same as among the European Population.\u00a0\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n<li><span style=\"font-family: georgia, palatino, serif;\"><strong>Fifth<\/strong>, several data and reports have suggested the Vaccine hesitancy among people due to Emergency Use authorization. Approval without even base-level data will only strengthen this hesitancy among the public.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: georgia, palatino, serif;\">The rush to approve the COVID-19 vaccine without proper clinical trial may do more harm than good. So, it would be better to wait for the preliminary data from the phase-III trials to come in, and then grant the approval.\u00a0<\/span><\/p>\n<p><span style=\"font-family: georgia, palatino, serif;\"><span style=\"font-size: 14pt;\"><strong>What is the way forward?<\/strong><\/span>\u00a0<\/span><\/p>\n<ul>\n<li><span style=\"font-family: georgia, palatino, serif;\">Government needs to strengthen its vaccine distribution and administration mechanism to meet the need of 1\/4<sup>th<\/sup> of the population it is looking to vaccinate in the first phase.<\/span><\/li>\n<li><span style=\"font-family: georgia, palatino, serif;\">Immunogenicity of both the vaccines could vary, thus there is a need to understand the adverse effects.<\/span><\/li>\n<li><span style=\"font-family: georgia, palatino, serif;\">Prioritising the elderly people needs to be re-examined because the elderly are <strong>less mobile and<\/strong>\u00a0have a\u00a0<strong>lower level of social interaction<\/strong>, they are less likely to spread the virus. So, in the long run, prioritizing the elderly people may not actually minimize the total <strong>social and economic cost\u00a0<\/strong>inflicted by the virus.<\/span><\/li>\n<li><span style=\"font-family: georgia, palatino, serif;\">Surveillance and monitoring systems will require to be tweaked as per the efficiency and effectiveness data of the Vaccine.<\/span><\/li>\n<li><span style=\"font-family: georgia, palatino, serif;\">Vaccinators required to be educated on the finer details of the two vaccines.<\/span><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>This article has been developed based on the Indian Express article \u201cTurning point\u201d. Synopsis-\u00a0The Drug Controller General of India (DCGI) approved two vaccines \u2014 the indigenously developed Covaxin, and Covishield. There are several concerns associated with the hasty approval of vaccines. About Vaccines COVISHIELD: This vaccine is incubated in the laboratories of Oxford University and&hellip; <a class=\"more-link\" href=\"https:\/\/forumias.com\/blog\/approval-to-covaxin-and-covishield-vaccines-concerns-and-way-forward\/\">Continue reading <span class=\"screen-reader-text\">Approval to Covaxin, and Covishield Vaccines: Concerns and way forward<\/span><\/a><\/p>\n","protected":false},"author":61,"featured_media":75355,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":""},"categories":[130],"tags":[1289,1456,1472],"class_list":["post-75368","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-7-pm","tag-soc_0","tag-soc_01","tag-vaccine_related_issues","entry"],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/forumias.com\/blog\/wp-content\/uploads\/2021\/01\/Concerns-of-hasty-approval-to-COVID-19-vaccine.jpg?fit=1280%2C720&ssl=1","views":{"total":0,"cached_at":"","cached_date":1704897991},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/75368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/users\/61"}],"replies":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/comments?post=75368"}],"version-history":[{"count":0,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/75368\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/media\/75355"}],"wp:attachment":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/media?parent=75368"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/categories?post=75368"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/tags?post=75368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}